Rituximab (RTX) as an alternative to TNF-alpha antagonists in patients with rheumatoid arthritis and high risk of severe infections: A systematic analysis of the experience in one center

Open Rheumatology Journal

Volumn 6, Issue 1, 2012, Pages 286-289

  Xanthouli, P ^a   Sailer, S ^a   Fiehn, C ^a  

^a ACURA Center for Rheumatic Diseases   (Germany)

Author keywords

Infections; Rheumatoid arthritis; Rituximab; TNF alpha antagonists

Indexed keywords

ISONIAZID; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABSCESS; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BRONCHITIS; CLINICAL ARTICLE; DRUG EFFICACY; DRUG WITHDRAWAL; EAR ABSCESS; EAR INFECTION; FEMALE; HIGH RISK PATIENT; HUMAN; INFECTION; INFECTION RISK; INFECTIOUS COMPLICATION; MALE; MULTIPLE CYCLE TREATMENT; PNEUMONIA; PRIORITY JOURNAL; RECURRENT INFECTION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SURGICAL INFECTION; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84871016290     PISSN: None     EISSN: 18743129     Source Type: Journal    
DOI: 10.2174/1874312901206010286     Document Type: Article

References (12)

1. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54(8): 2368-76.
2. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-celltargeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350(25): 2572-81.
3. van Vollenhoven RF, Emery P, Bingham CO, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 2010; 37(3): 558-67.
4. Gottenberg JE, Ravaud P, Bardin T, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010; 62(9): 2625-32.
5. Chatzidionysious K, Carli C, van Vollenhofen RF. Rituximab versus anti-TNF in patients who previously failed one or more anti-TNFs on an observational cohort: the SARASTRA study. Ann Rheum Dis 2009; 68(Suppl 3): 445.
6. Gomez-Reino J, Sanmarti R, Romero AB, Monclus L. Switching to riruximab vs TNF-inhibitor cycling in patients with an inadequate response to TNF-inhibitors: the MIRAR study. Ann Rheum Dis 2009; 69(Suppl 3): 538.
7. Finckh A, Ciurea A, Brulhart L, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 2010; 69(2): 387-93.
8. Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011; 70: 1914-20.
9. Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65(7): 889-94.
10. Kremer JM, Genant HK, Moreland LW, et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008; 58(4): 953-63.
11. Genovese MC, Schiff M, Luggen M, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008; 67(4): 547-54.
12. Toussirot E, Pertuiset E, Sordet C, et al. Safety of rituximab in rheumatoid arthritis patients with a history of severe or recurrent bacterial infection: observational study of 30 cases in everyday practice. Joint Bone Spine 2010; 77: 142-5.